The mission of St. Jude Children's Research Hospital is to find cures for children with catastrophic illnesses through research and treatment. The resources of the hospital have been focused on pediatric cancer throughout its 44 year history and the Cancer Center has been supported by a CCSG for 29 years. Through the support of the American Lebanese Syrian Associated Charities (ALSAC), a separate corporation whose only purpose is to raise money in support of St. Jude Children's Research Hospital, patients are accepted without regard to ability to pay. Public support of the hospital through ALSAC provides a strong foundation for our Cancer Center upon which extramurally funded research and CCSG support can be leveraged to their fullest potential. In the current application, six multidisciplinary research programs are described. The Molecular Oncology (MO) and Signal Transduction (ST) Programs focus on basic, discovery-oriented research. The Developmental Therapeutics for Solid Malignancies (DTSM), Hematologic Malignancies (HM), Neurobiology and Brain Tumor (NBT), and Cancer Prevention and Control (CPC) Programs emphasize the translation of laboratory or population science to clinical application. The latter program is new to this application and represents the culmination of a long-standing commitment to long-term follow-up of our patient population, a recent commitment to population sciences, and successful recruitment of a world-class scientist to lead efforts in this area. Research by the 139 members of the Cancer Center is supported by 12 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Cancer Center Director was appointed and the overall structure of our Cancer Center and its leadership were enhanced by several organizational changes, including bringing the infrastructure supporting the expansive clinical trials efforts administratively under the Cancer Center's authority. Several Program leader changes and the successful recruitment of three new outstanding Department Chairs (Immunology, Chemical Biology, and Epidemiology/Cancer Control) during the last funding period significantly enhance the multidisciplinary science done by our Cancer Center Programs. St. Jude Cancer Center investigators had over 2000 cancer-related publications during the funding period, 20% of which represented intraprogrammatic interactions and 15% of which were inter-programmatic. Extramural support for cancer research done at St. Jude is currently over $50 million per year, $31 million of which is from the NCI/HHMI. St. Jude Children's Research Hospital recently went through a vigorous Strategic Planning process and made a strong and long-term commitment to remain focused on cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-34S1
Application #
8396530
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z (O1))
Program Officer
Lin, Alison J
Project Start
1997-04-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2014-02-28
Support Year
34
Fiscal Year
2012
Total Cost
$122,220
Indirect Cost
$49,470
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Devine, Katie A; Mertens, Ann C; Whitton, John A et al. (2018) Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: A report from the childhood cancer survivor study (CCSS). Psychooncology 27:613-619
Matreyek, Kenneth A; Starita, Lea M; Stephany, Jason J et al. (2018) Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat Genet 50:874-882
Hazlitt, Robert A; Min, Jaeki; Zuo, Jian (2018) Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss. J Med Chem 61:5512-5524
Hoehn, Mary Ellen; Calderwood, Julie; Gannon, Edwin et al. (2018) Ocular complications in a young pediatric population following bone marrow transplantation. J AAPOS 22:102-106.e1
Zimmerman, Mark W; Liu, Yu; He, Shuning et al. (2018) MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov 8:320-335
Hammill, Jared T; Bhasin, Deepak; Scott, Daniel C et al. (2018) Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem 61:2694-2706
Li, Yanfeng; Bakke, Jesse; Finkelstein, David et al. (2018) HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. Oncogenesis 7:9
Khan, Raja B; Merchant, Thomas E; Sadighi, Zsila S et al. (2018) Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. J Neurooncol 136:379-384
Ma, Xiaotu; Liu, Yu; Liu, Yanling et al. (2018) Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555:371-376
Broniscer, Alberto; Jia, Sujuan; Mandrell, Belinda et al. (2018) Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer 65:e27035

Showing the most recent 10 out of 6764 publications